End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
31.26 CNY | -0.29% | +1.49% | +4.58% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- With regards to fundamentals, the enterprise value to sales ratio is at 0.87 for the current period. Therefore, the company is undervalued.
- The company has a low valuation given the cash flows generated by its activity.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company is not the most generous with respect to shareholders' compensation.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Drug Retailers
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+4.58% | 2.53B | C+ | ||
-9.33% | 3.67B | D+ | ||
-1.81% | 3.34B | D- | ||
-21.97% | 3.18B | D | ||
+9.29% | 2.8B | - | ||
-11.44% | 1.68B | - | ||
+11.09% | 1.39B | - | - | |
-19.03% | 981M | - | ||
-40.19% | 684M | - | - | |
-0.53% | 455M | - | D+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 603883 Stock
- Ratings LBX Pharmacy Chain